United Therapeutics Initiates Enrollment of the First Patient in the Phase 3 Teton PPF Trial, Investigating the Use of Nebulized Tyvaso in Individuals with Progressive Pulmonary Fibrosis

Published: November 2023

On 31 October 2023, United Therapeutics announced the enrolment of first patient in the registration-phase TETON PPF study. The aim of the study is to evaluate nebulized Tyvaso® (treprostinil) Inhalation Solution in 698 adult patients suffering from progressive pulmonary fibrosis (PPF).

The 52-week study aims to evaluate the impact of nebulized Tyvaso on a key prognostic indicator for PPF known as forced vital capacity (FVC). PPF is a progressive form of interstitial lung disease (ILD) characterized by the loss of the ability of the lungs to transfer oxygen into the blood, ultimately resulting in respiratory failure and death.

Nebulized Tyvaso has been approved by the Food and Drug Administration (FDA) to treat both pulmonary arterial hypertension and pulmonary hypertension (PH) associated with interstitial lung disease (PH-ILD).

According to Roots Analysis, the Idiopathic Pulmonary Fibrosis Market is anticipated to grow at a stable rate during the forecast period.

For detailed insights about this domain, check out our report on Idiopathic Pulmonary Fibrosis Market or email sales@rootsanalysis.com

You may also be interested in the following titles:

MEDIA CITATIONS

With the wearable device market expected to provide a smart and straightforward drug delivery experience to patient populations worldwide..

Driven by the Growing Demand for Biologics, the Biopharmaceutical Contract Manufacturing Market is Expected to Grow at an Annualized Rate of 8.1%..

A new analysis by Roots Analysis has predicted that the antibody drug conjugates (ADC) market will be worth more than $15 billion by 2030, growing at a compound annual growth rate (CAGR) of over 20 percent due to their growing popularity and therapeu..

For kidneys, Roots Analysis, a medical-technology consultancy, reckons that should be possible in about six yearsâ€™ time. Livers, which have a natural tendency to regenerate anyway, should also arrive reasonably soon. Hearts, with their complex inte..

Roots Analysis predicts the gene therapy market as a whole to reach ~$11 bln by 2025..

Roots Analysis, a market research and consulting firm for the pharmaceutical industry, says that growth will add to the estimated â€œcurrent global contract pharmaceutical installed manufacturing capacity of 125 million liters [30.4 million U.S. gall..

There are few companies with the capability to commercially manufacture viral vectors; most of the 24 firms identified by Roots Analysis in a 2016 report are CDMOs...

Roots Analysis estimates there are over 500 gene therapy candidates in clinical development, with approximately 1,700 clinical studies underway around the world...

We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry

United Therapeutics Initiates Enrollment of the First Patient in the Phase 3 Teton PPF Trial, Investigating the Use of Nebulized Tyvaso in Individuals with Progressive Pulmonary Fibrosis

Novo Nordisk Invested EUR 2.1 Billion in a French Manufacturing Site to Meet Growing Demand for Diabetes and Obesity Therapies

Autism and Maternal Immune Activation: Groundbreaking Insights

Market Insights Reports

Indication Specific Reports

Who we are

Our Team

FAQ's

United Therapeutics Initiates Enrollment of the First Patient in the Phase 3 Teton PPF Trial, Investigating the Use of Nebulized Tyvaso in Individuals with Progressive Pulmonary Fibrosis

Novo Nordisk Invested EUR 2.1 Billion in a French Manufacturing Site to Meet Growing Demand for Diabetes and Obesity Therapies

Autism and Maternal Immune Activation: Groundbreaking Insights